Development

Editor of Pharmaceutical Technology Europe

Articles

Dissolution testing is experiencing a refresh thanks to a variety of market drivers.

Building Up to a Bright Future

Meg Rivers is the former senior editor for 

Podcasts

Experts from Umoja Biopharma dive into cell therapy development in this episode of the Drug Solutions Podcast, including the greatest advancements in cell therapy to date, areas for improvement, the biggest trends in cell therapy development, and retention as a pain point. 

Drug Solutions Podcast: Cell Therapy Development: Advances, Trends, and the Challenge of Retention

Chris Spivey is the editorial director of 

As we reach further afield in the molecular universe, we encounter new types of problems to resolve.

Process Development Struggles with Molecular Diversity

Avid Bioservices has expanded its viral vector development and manufacturing facility with the addition of analytical and process development suites.

Avid Bioservices Launches New Analytical and Process Development Suites at Viral Vector Facility

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Flexible and efficient methods are needed for biopharmaceutical manufacturing. 

Demonstrating a Fully Continuous Bioprocess

Joan Piedrafita is the digital development project manager at Telstar.

Xavier Olivella is a global customer service engineer at Telstar.

Digital maintenance solutions can help visualize the value and key activities provided by the equipment vendor from inception to utilization.

Key Factors in the Development of Data Analytics for Industrial Pharmaceutical Equipment

Developers need to consider key challenges when approaching accelerated formulation strategies to ensure success.

Successfully Accelerating Formulation Strategies

Noema Pharma announces first patient dosed in its Phase IIb clinical trial of mGluR5 inhibitor NOE-101 in trigeminal neuralgia.

Noema Pharma Announces First Patient Dosed in Study Evaluating Efficacy of NOE-101 for Trigeminal Neuralgia

Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants. 

What’s Next for COVID-19 Vaccines and Variants?

Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.